by Alison Bass | Nov 2, 2011 | antipsychotic drugs, conflicts of interest, drug marketing, ghostwriting, patient care, pharmaceutical industry, scientific misconduct, Uncategorized
On November 28, the Texas Attorney General is expected to begin a landmark trial against Johnson & Johnson on charges that the pharmaceutical giant “subverted scientific integrity” by paying off academic psychiatrists and state officials to boost the...
by Alison Bass | Aug 10, 2011 | drug marketing, ghostwriting, medical devices, scientific journal retractions, university industry collaboration
The retraction of studies in medical and scientific journals has surged in the last decade, according to separate analyses done by the Wall Street Journal and Retraction Watch. In its page-one article today, the Journal noted that while just 22 retraction notices...
by Alison Bass | Jul 20, 2011 | conflicts of interest, drug marketing, National Institutes of Health, university industry collaboration
I realize this is the dead of summer and every journalist who isn’t on vacation is captivated by the Murdoch phone-hacking scandal. But while everyone is looking the other way, the National Institute of Health’s proposed new rules about the disclosure of...
by Alison Bass | Jun 27, 2011 | biotech industry, conflicts of interest, drug marketing, health care costs, medical devices, pharmaceutical industry
A page-one story in The Boston Globe today spotlights the Massachusetts biotech industry’s effort to block a key piece of President Obama’s health care overhaul: the creation of an independent payment advisory board (IPAB) that would make recommendations...
